IPO Testimony to U.S. ITC Regarding COVID-19 Diagnostics and Therapeutics: Supply, Demand, and TRIPS Agreement Flexibilities
IPO Testimony to U.S. ITC Regarding COVID-19 Diagnostics and Therapeutics: [...]
IPO Response to Questions Re: USTR 2023 Special 301 Review
IPO Response to Questions Re: USTR 2023 Special 301 Review
IPO Comments to CNIPA on Draft Amendment to the Trademark Law
IPO Comments to CNIPA on Draft Amendment to the Trademark [...]
IPO’s Comments on the Draft 2022-2026 USPTO Strategic Plan
IPO’s Comments on the Draft 2022-2026 USPTO Strategic Plan
IPO Comments on Joint USPTO–FDA Collaboration Initiatives
IPO Comments on Joint USPTO–FDA Collaboration Initiatives
IPO Comments Regarding USPTO Initiatives To Ensure the Robustness and Reliability of Patent Rights
IPO Comments Regarding USPTO Initiatives To Ensure the Robustness and [...]
IPO Comments Regarding Expanding Opportunities to Appear Before the Patent Trial and Appeal Board
IPO Comments Regarding Expanding Opportunities to Appear Before the Patent [...]
IPO Comments Regarding Expanding Admission Criteria for Registration to Practice in Patent Cases Before the United States Patent and Trademark Office
IPO Comments Regarding Expanding Admission Criteria for Registration to Practice [...]
IPO 2023 Special 301 Review Comments
IPO 2023 Special 301 Review Comments
IPO Comments to UKIPO Regarding Transformation Consultation
IPO Comments to UKIPO Regarding Transformation Consultation
Posts tagged here will show on the testimony and comments page.